Revvity, Inc. (PKN.F)
Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Prahlad R. Singh Ph.D. | CEO, President & Director | 3.25M | 1.98M | 1965 |
Mr. Maxwell Krakowiak | Senior VP & CFO | 1.01M | -- | 1990 |
Mr. Tajinder S. Vohra | Senior Vice President of Global Operations | 886.88k | 355.26k | 1966 |
Mr. Joel S. Goldberg | Senior VP of Administration, General Counsel & Secretary | 1.17M | 1.03M | 1969 |
Ms. Miriame Victor | Senior VP & Chief Commercial Officer | 904.24k | -- | 1982 |
Mr. Bryan A. Kipp | Senior VP of Technology & Licensing | -- | -- | -- |
Ms. Madhuri Hegde FACMG, Ph.D. | Senior VP & Chief Scientific Officer | -- | -- | -- |
Mr. Stephen Barr Willoughby | Senior VP of Investor Relations & Head of ESG | -- | -- | -- |
Ms. Magali Four | Senior VP and Chief People & Culture Officer | -- | -- | -- |
Mr. Robert Francis Friel | Advisor | 6.09M | -- | 1956 |
Revvity, Inc.
- Sector:
- Healthcare
- Industry: Diagnostics & Research
- Full Time Employees:
- 11,000
Description
Revvity, Inc. provides health sciences solutions, technologies, and services worldwide. The company's Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and DNA sequencing services. Its Diagnostics segment offers instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. It also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for use in oncology, screening newborns for rare genetic conditions, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific, BioQule, BoBs, chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPatternTM, Evolution Evoya, explorer, Fontus, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Omni Bead Ruptor, Omni Bead Ruptor Elite, Omni Tip, Pannoramic, Panthera Puncher, PG-Seq, PG-Find, PreNAT II, Prime, Protein Clear, ProteinEXact, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord, VICTOR2D, and Zephyr brands. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Corporate Governance
Upcoming Events
April 28, 2025 at 12:30 PM UTC
Revvity, Inc. Earnings Date
Recent Events
April 17, 2025 at 12:00 AM UTC
Ex-Dividend Date